Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.

Autor: Freedman MS; Department of Medicine, University of Ottawa, Ottawa, ON, K1H 8L6, Canada. mfreedman@toh.ca.; The Ottawa Hospital Research Institute, 501 Smyth, Ottawa, ON, K1H 8L6, Canada. mfreedman@toh.ca., Coyle PK; Department of Neurology, Renaissance School of Medicine, Stony Brook University, New York, NY, 11794, USA., Hellwig K; Katholisches Klinikum Bochum, Ruhr University, 44787, Bochum, Germany., Singer B; The MS Center for Innovations in Care, Missouri Baptist Medical Center, 3009 N. Ballas Road, Suite 105B, St. Louis, MO, 63131, USA., Wynn D; Neurology MS Center, Consultants in Neurology, Ltd, 1535 Lake Cook Road, Suite 601, Northbrook, IL, 60062, USA., Weinstock-Guttman B; Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY, 14215, USA.; Jacobs MS Center for Treatment and Research, Buffalo, NY, 14202, USA.; Pediatric MS Center, NY State MS Consortium, 1010 Main Street, Buffalo, NY, 14203, USA., Markovic-Plese S; Division of Neuroimmunology, Department of Neurology, Thomas Jefferson University, 900 Walnut St, Rm 305-B, Philadelphia, PA, 19107, USA., Galazka A; Merck Healthcare KGaA, 64293, Darmstadt, Germany., Dangond F; EMD Serono Research & Development Institute Inc., an affiliate of Merck GKaA, Billerica, MA, 01821, USA., Korich J; EMD Serono Inc., an affiliate of Merck KGaA, Rockland, MA, 02370, USA., Reder AT; Department of Neurology A-205, University of Chicago Medicine, MC-2030, 5841 S Maryland Ave, Chicago, IL, 60637, USA.

Publikováno v: Neurology and therapy [Neurol Ther] 2024 Apr; Vol. 13 (2), pp. 283-322. Date of Electronic Publication: 2024 Jan 11.

Rebif® Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis

Autor: Bandari, D., Wynn, D., Miller, T., Singer, B., Wray, S., Bennett, R., Hayward, B., Dangond, F.

Publikováno v: In Multiple Sclerosis and Related Disorders January 2013 2(1):45-56

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.

Autor: Giovannoni G; Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK., Comi G; Casa di Cura Privata del Policlinico, Universita Vita-Salute San Raffaele, Milan, Italy., Rammohan K; MS Research Center, University of Miami School of Medicine, Miami, FL, USA., Rieckmann P; Department of Neurology, Medical Park Loipl & University of Erlangen, Erlangen, Germany., Dangond F; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA., Jack D; Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA., Vermersch P; Univ. Lille, INSERM U1172, Lille Neurosciences & Cognition, CHU Lille, FHU Precise, Lille, France.

Publikováno v: Neurodegenerative disease management [Neurodegener Dis Manag] 2022 Dec; Vol. 12 (6), pp. 295-301. Date of Electronic Publication: 2022 Aug 26.

Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.

Autor: Stefano N; Department of Neurological & Behavioural Sciences, University of Siena, Siena, Italy/Department of Medicine, Surgery & Neuroscience, University of Siena, Siena, Italy., Sormani MP; Department of Health Sciences, University of Genoa & Ospedale Policlinico San Martino IRCCS, Genoa, Italy., Giovannoni G; Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK., Rammohan K; Department of Neurology, University of Miami School of Medicine, MS Research Center, Miami, FL, USA., Leist TP; Division of Clinical Neuroimmunology, Jefferson University, Comprehensive MS Center, Philadelphia, PA, USA., Coyle PK; Department of Neurology, Stony Brook University, Stony Brook, NY, USA., Dangond F; EMD Serono Research & Development Institute Inc., Billerica, MA, USA, an affiliate of Merck KGaA., Alexandri N; Merck Healthcare KGaA, Darmstadt, Germany., Galazka A; Merck Healthcare KGaA, Darmstadt, Germany.

Publikováno v: Neurodegenerative disease management [Neurodegener Dis Manag] 2022 Dec; Vol. 12 (6), pp. 303-310. Date of Electronic Publication: 2022 Aug 26.